Community-acquired CTX-M-15-type ESBL-producing Escherichia coli meningitis: a case report and literature review

Creative Commons License

ELALDI N., GÖZEL M. G., KOLAYLI F., ENGİN A., ÇELİK C., BAKICI M. Z., ...Daha Fazla

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.7, sa.5, ss.424-431, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 7 Sayı: 5
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3855/jidc.2820
  • Dergi Adı: JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.424-431
  • Anahtar Kelimeler: Escherichia coli, CTX-M-15, meningitis, SPECTRUM-BETA-LACTAMASE, URINARY-TRACT-INFECTIONS, BACTERIAL-MENINGITIS, RISK-FACTORS, ENTEROBACTERIACEAE, TURKEY, EPIDEMIOLOGY, RESISTANCE, UNIVERSITY, MORTALITY
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

In this report, a case of community-acquired acute bacterial meningitis (CA-ABM) caused by CTX-M-15-producing Escherichia coli in an elderly male patient was presented in the light of literature. Cultures of cerebrospinal fluid, blood, ear discharge, and stool samples yielded CTX-M-15-producing E. coli in-vitro, which was resistant to the extended-spectrum cephalosporins and ciprofloxacin and susceptible to imipenem, meropenem and amikacin. Meningitis was treated with parenteral meropenem plus parenteral and intraventricular amikacin administration. Since bacterial meningitis is a life-threatening infection, empiric antibiotic therapy with carbapenem can be started before the culture results are obtained, mainly in areas where the ESBL epidemiology is well known.